This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (81)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Surgical Oncology  • Women's Health  • Women's Health, Other  • Breast Cancer  • Alert me on articles by topic

D. Kay Blanchard, MD, PhD; John H. Donohue, MD; Carol Reynolds, MD; Clive S. Grant, MD

Arch Surg. 2003;138:482-488.

Hypothesis  Axillary relapse in node-negative patients staged with sentinel lymph node (SLN) biopsy alone is no more frequent than in patients treated with standard axillary dissection. Morbidity is less for patients who had SLN biopsy.

Design, Setting, and Patients  Between October 14, 1997, and August 31, 2001, 1253 consecutive women with primary invasive breast cancer were prospectively entered into an SLN biopsy database. Completion axillary dissection was performed in 164 patients after SLN biopsy as part of a training protocol.

Interventions  Patients were contacted by questionnaire or telephone to determine breast cancer relapse; presence of arm lymphedema, arm pain, axillary infection, or seroma formation; and tumor recurrence or death.

Main Outcome Measures  ² or Fisher exact tests and Wilcoxon rank sum tests were used to analyze categorical and continuous variables. Logistic regression was used to analyze morbidity.

Results  Of 1253 women, 894 (71%) were node negative by SLN biopsy alone (n = 730 [82%]) or SLN biopsy and completion axillary dissection (n = 164 [18%]). Questionnaires were completed by 776 patients (87%). Mean ± SD follow-up was 2.4 ± 0.9 years. Patients with axillary dissections reported a significantly higher occurrence of arm lymphedema (34%), arm pain (38%), seroma formation (24%), and infection (9%) vs SLN biopsy–only patients (6%, 14%, 7%, and 3%, respectively). One axillary relapse (0.1%) occurred during follow-up of 685 women who underwent SLN biopsy only.

Conclusions  With intermediate-term follow-up, there was 1 axillary recurrence in 685 SLN node-negative women, supporting use of SLN biopsy as an accurate method for staging breast cancer. Biopsy of the SLN was associated with significantly less morbidity than completion axillary dissection.

From the Departments of Surgery (Drs Blanchard, Donohue, and Grant) and Pathology (Dr Reynolds), Mayo Clinic, Rochester, Minn.

RELATED ARTICLE

This Month in Archives of Surgery
Arch Surg. 2003;138(5):469.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Quality of Life After Sentinel Lymph Node Biopsy or Axillary Lymph Node Dissection in Stage I/II Breast Cancer Patients: A Prospective Longitudinal Study
Kootstra et al.
Ann. Surg. Oncol. 2008;15:2533-2541.
ABSTRACT | FULL TEXT  

Long-Term Morbidity of Sentinel Node Biopsy Versus Complete Axillary Dissection for Unilateral Breast Cancer
Crane-Okada et al.
Ann. Surg. Oncol. 2008;15:1996-2005.
ABSTRACT | FULL TEXT  

Axillary recurrence in sentinel lymph node-negative breast cancer patients
Poletti et al.
Ann Oncol 2008;0:mdn393v1-mdn393.
ABSTRACT | FULL TEXT  

Disparities and Trends in Sentinel Lymph Node Biopsy Among Early-Stage Breast Cancer Patients (1998-2005)
Chen et al.
JNCI J Natl Cancer Inst 2008;100:462-474.
ABSTRACT | FULL TEXT  

Blue Dye Injection in the Arm in Order to Conserve the Lymphatic Drainage of the Arm in Breast Cancer Patients Requiring an Axillary Dissection
Nos et al.
Ann. Surg. Oncol. 2007;14:2490-2496.
ABSTRACT | FULL TEXT  

Human lymphatic pumping measured in healthy and lymphoedematous arms by lymphatic congestion lymphoscintigraphy
Modi et al.
J. Physiol. 2007;583:271-285.
ABSTRACT | FULL TEXT  

Axillary Reverse Mapping (ARM): A New Concept to Identify and Enhance Lymphatic Preservation
Thompson et al.
Ann. Surg. Oncol. 2007;14:1890-1895.
ABSTRACT | FULL TEXT  

Can Surgical Oncologists Reliably Predict the Likelihood for Non-SLN Metastases in Breast Cancer Patients?
Smidt et al.
Ann. Surg. Oncol. 2007;14:615-620.
ABSTRACT | FULL TEXT  

Micrometastases in Sentinel Lymph Node in a Multicentric Study: Predictive Factors of Nonsentinel Lymph Node Involvement--Groupe Des Chirurgiens De La Federation Des Centres De Lutte Contre Le Cancer
Houvenaeghel et al.
JCO 2006;24:1814-1822.
ABSTRACT | FULL TEXT  

Axillary Ultrasonography to Detect Recurrence After Sentinel Node Biopsy in Breast Cancer
Snider et al.
Ann. Surg. Oncol. 2006;13:501-507.
ABSTRACT | FULL TEXT  

Older Age Independently Predicts a Lower Risk of Sentinel Lymph Node Metastasis in Breast Cancer
Caywood et al.
Ann. Surg. Oncol. 2005;12:1061-1065.
ABSTRACT | FULL TEXT  

Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer Patients
Newman
J Oncol Pract 2005;1:130-133.
FULL TEXT  

The Effect of Sentinel Node Tumor Burden on Non-Sentinel Node Status and Recurrence Rates in Breast Cancer
Fan et al.
Ann. Surg. Oncol. 2005;12:705-711.
ABSTRACT | FULL TEXT  

Breast Biopsy Utilization: A Population-Based Study
Ghosh et al.
Arch Intern Med 2005;165:1593-1598.
ABSTRACT | FULL TEXT  

Incidence and Clinical Significance of Lymph Node Metastasis Detected by Cytokeratin Immunohistochemical Staining in Ductal Carcinoma In Situ
El-Tamer et al.
Ann. Surg. Oncol. 2005;12:254-259.
ABSTRACT | FULL TEXT  

Can Sentinel Lymph Node Biopsy Be Omitted in Patients With Favorable Breast Cancer Histology?
Mendez et al.
Ann. Surg. Oncol. 2005;12:24-28.
ABSTRACT | FULL TEXT  

Axillary Recurrence After a Negative Sentinel Node Biopsy for Breast Cancer: Incidence and Clinical Significance
Smidt et al.
Ann. Surg. Oncol. 2005;12:29-33.
ABSTRACT | FULL TEXT  

Axillary Recurrence After Sentinel Node Biopsy
Jeruss et al.
Ann. Surg. Oncol. 2005;12:34-40.
ABSTRACT | FULL TEXT  

Sentinel Lymph Node Metastases Detected by Immunohistochemistry Only Do Not Mandate Complete Axillary Lymph Node Dissection in Breast Cancer
Gray et al.
Ann. Surg. Oncol. 2004;11:1056-1060.
ABSTRACT | FULL TEXT  

Treatment-Related Upper Limb Morbidity 1 Year after Sentinel Lymph Node Biopsy or Axillary Lymph Node Dissection for Stage I or II Breast Cancer
Rietman et al.
Ann. Surg. Oncol. 2004;11:1018-1024.
ABSTRACT | FULL TEXT  

Invited Commentary * Authors' Response
Dillehay et al.
RadioGraphics 2004;24:139-145.
FULL TEXT  

The Eternally Enigmatic Axilla: Further Controversy About Axillary Lymph Nodes in Breast Cancer
McMasters
Ann. Surg. Oncol. 2003;10:1128-1130.
FULL TEXT